# NCT05877820 (NCT05877820)

> A Study to Evaluate Efficacy and Safety of Lenvatinib Combined With Tislelizumab in Patients With FHRCC

No report yet. It can be ordered.

- Drugs tested: lenvatinib plus tislelizumab
- Indication: first-line advanced fumarate hydratase-deficient renal cell carcinoma

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT05877820
- Phase: PHASE2
- Status: COMPLETED
- Sponsor: RenJi Hospital
- Conditions: Fumarate Hydratase Deficient Renal Cell Carcinoma
- Interventions: Tislelizumab; Lenvatinib
- Enrollment: 20
- Primary outcome: Objective Response Rate (ORR) Per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1)

## Indexed commentary on NCT05877820 so far

Podcasts, YouTube videos and X posts we have indexed that name the trial. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- 3 posts on X

## Order

Focused, $750 at most (a smaller delivered size costs its own price): https://www.erudio.com/contact?report=nct05877820